News

lupus.bmj1d
LP-150 Outcomes of serologically active clinically quiescent (SACQ) versus serologically and clinically quiescent (SQCQ) statuses in patients with systemic lupus erythematosus
Background To compare the prognosis of SLE patients who achieve clinically quiescent following treatment, with or without serologically active. Methods We categorized SLE patients from Lupus Clinic of ...
lupus.bmj3d
Independent association of glucocorticoids with damage accrual in SLE
Objectives To determine factors associated with damage accrual in a prospective cohort of patients with SLE. Methods Patients with SLE who attended the Lupus Clinic at Monash Health, Australia, ...
lupus.bmj3d
PO.5.108 Combined model of renal histopathology and clinical parameters better predicts one-year renal outcomes in lupus nephritis: analysis of 334 kidney biopsies
Background/Purpose Diagnosis of Lupus Nephritis (LN) is currently based on laboratory tests and renal histopathology. The role of histopathological features in determining long term outcomes is ...
lupus.bmj3d
Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival
Objectives While diffuse alveolar haemorrhage (DAH) is recognised as a life-threatening complication of systemic lupus erythematosus (SLE), little is known about its risk factors and response to ...
lupus.bmj5d
Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis
Objective To describe the pharmacodynamic monitoring of (immuno)proteasome inhibition following treatment with bortezomib in a therapy-refractory systemic lupus erythematosus (SLE) patient with ...
lupus.bmj5d
Evaluating the concordance between BICLA and SRI4 in patients with systemic lupus erythematosus from the placebo arms of the EXPLORER and ATHOS trials
Objective The British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and the Systemic Lupus Erythematosus Responder Index 4 (SRI4) responses are the most common primary ...
lupus.bmj6d
Table of contents
Parallel Session 4: Lupus reflections across the continents: are we addressing the needs of our patients? Parallel Session 4: Lupus reflections across the continents: are we addressing the needs of ...
lupus.bmj6d
SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies
Objectives This study aimed to derive and validate a cut-off for severe disease activity (SDA) using the SLE Disease Activity Score (SLE-DAS) and compare its accuracy and impact on health-related ...
lupus.bmj8d
Lupus pathogenesis and autoimmunity are exacerbated by high fat diet-induced obesity in MRL/lpr mice
Objective SLE is an autoimmune disease characterised by persistent inflammation and autoantibody production. Genetic predisposition and environmental factors such as a high-fat diet (HFD) may ...
lupus.bmj8d
Real-world treatment patterns, healthcare resource utilisation and costs in patients with SLE in the USA
Objective To evaluate the treatment patterns, medication adherence, concomitant corticosteroid use, factors influencing sequence of therapies (SOTs), healthcare resource utilisation (HCRU) and ...
lupus.bmj9d
601 Association of sleep deprivation and the risk of developing systemic lupus erythematosus among women
Objective Sleep deprivation has been associated with risk of autoimmune diseases. We investigated whether it was associated with risk of developing SLE using the Nurses’ Health Study (NHS) (1986-2016) ...
lupus.bmj9d
Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis
Objective To investigate second kidney biopsy as predictor of end-stage kidney disease (ESKD) in active lupus nephritis (LN). Methods Patients with biopsy-proven LN (International Society of ...